ArticleAnnals of surgical oncology2026

ASO Author Reflections: Translating Trial Evidence into Real-World Benefit: First-Line Pembrolizumab in Advanced NSCLC.

Guilherme Franceschini Machado et al.PubMed ↗Publisher ↗

No numbers read from the abstract.